This article was written in 4-2016 about RGBP’s relationship with Eli Lilly.
“Regen BioPharma is a LONG PLAY that has experienced and multiple times realized Short Term Gains” said Robert E. Kreh
I believe it’s NRF26 is already on Eli Lilly’s radar.
Quote:
“And now today an Agreement with Eli Lilly and Company. RGBP is Poised to become a Major Player in the Stem Cell Arena and/or a very Attractive Candidate for Buy Out”